SCHEMBL7654522

SCHEMBL7654522

CC(=O)On1c(=O)c(-c2cn(Cc3ccc(CN)cc3)c3ccccc23)nc2cc3ccccc3cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
PDE4A P27815 8/20 0.40
PDE4B Q07343 8/20 0.40
PDE4C Q08493 8/20 0.40
PDE4D Q08499 8/20 0.40
PDE3B Q13370 5/20 0.40
PDE3A Q14432 5/20 0.40
PRKCB P05771 2/20 0.39
PRKCA P17252 2/20 0.39
PRKCH P24723 1/20 0.39
PRKCE Q02156 1/20 0.39
PRKCQ Q04759 1/20 0.39
PRKCD Q05655 1/20 0.39
CHRM1 P11229 2/20 0.38
SIRT2 Q8IXJ6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7657926 0.95 USP2 (0.41) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL7851651 0.91 PDE4A (0.38) CA12CA1CA2CA9PDE4A
SCHEMBL7659856 0.91 PDE4A (0.38) ALDH1A1CA12CA1CA2CA9
SCHEMBL7663917 0.90 PDE4A (0.38) CA12CA1CA2CA9PDE4A
SCHEMBL7662878 0.90 ACKR3 (0.36) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL7664799 0.89 PDE4A (0.37) CA12CA1CA2CA9PDE4A
SCHEMBL7659626 0.87 CAMK2D (0.43) ALDH1A1PRKCBPRKCAPRKCHPRKCQ
SCHEMBL7664699 0.87 POLB (0.36) ALDH1A1SMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL7652540 0.86 PDE4A (0.37) CA12CA1CA2CA9PDE4A
SCHEMBL7662061 0.86 POLB (0.38) CA12CA1CA2CA9PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US disclosed
EP-1071683-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2001-01-31 EP disclosed
WO-1999046264-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-09-16 WO disclosed